AnaptysBio

Yahoo Finance • 30 days ago

J.P. Morgan Maintains a Sell Rating on GSK plc (GSK)

GSK plc (NYSE:GSK) is one of the best pharma stocks to invest in. J.P. Morgan analyst Richard Vosser maintained a Sell rating on GSK plc (NYSE:GSK) on December 8, setting a price target of £17.00.Is GSK plc (GSK) the Best Undervalued UK St... Full story

Yahoo Finance • last month

Quality stocks present “once in a generation” opportunity – top stocks as per SA Quant

[Businessman showing the upward arrow on the chart. Technology innovation on a virtual screen. Concept of development and growth business efficiency, and increase productivity] leolintang/iStock via Getty Images Investors facing historica... Full story

Yahoo Finance • last month

SA Quant ranks Goldman's small-cap stocks with largest short interest

[Multi screen fintech investing gold and silver trading on digital screen corporating with AI artificial intelligence financial business data on commodity investment] primeimages Goldman Sachs analysts last week identified 50 small-cap st... Full story

Yahoo Finance • last month

Anaptys Announces Participation in December Investor Conferences

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executiv... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves midday: Oracle, Bath & Body Works, Gap and more

Check out the companies making the biggest moves midday: Oracle — The AI stock fell 4% as investors remained worried about valuations tied to AI continued to dump stocks. Those declines added to Oracle's and Nvidia's steep weekly losses. B... Full story

Yahoo Finance • 2 months ago

AnaptysBio drops as litigation with GSK unit risks cancer therapy deal

Evelyn Mccarthy/E+ via Getty Images AnaptysBio (ANAB [https://seekingalpha.com/symbol/ANAB]) shares lost ~11% in the premarket on Friday after the U.S. drugmaker and its partner Tesaro, a subsidiary of GSK (GSK [https://seekingalpha.com/s... Full story

Yahoo Finance • 2 months ago

AnaptysBio sets $100M stock repurchase plan

* AnaptysBio (ANAB [https://seekingalpha.com/symbol/ANAB]) board has authorized an amended stock repurchase plan to buy back up to $100.0 million of its outstanding common stock. * This amendment is in addition to the $6.4 million that... Full story

Yahoo Finance • 2 months ago

Anaptys Announces $100 Million Stock Repurchase Plan

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an... Full story

Yahoo Finance • 2 months ago

TESARO Pursues Litigation Against AnaptysBio For Alleged Material Breach Of Jemperli Agreement

(RTTNews) - GSK plc.'s (GSK) subsidiary TESARO Inc. has commenced litigation against AnaptysBio Inc. (ANAB), contending that AnaptysBio has materially violated the terms of their licensing agreement related to the oncology drug Jemperli.... Full story

Yahoo Finance • 2 months ago

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chance... Full story

Yahoo Finance • 2 months ago

GSK's Tesaro Sues AnaptysBio Over Jemperli License Dispute

(RTTNews) - GSK plc (GSK), a biopharmaceutical company's subsidiary Tesaro, Inc. (TSRO), on Friday announced that it has filed litigation in the Delaware Chancery Court against AnaptysBio, Inc. (ANAB), alleging a material breach of their l... Full story

Yahoo Finance • 2 months ago

Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executiv... Full story

Yahoo Finance • 2 months ago

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec. 2025Phase 2b data... Full story

Yahoo Finance • 2 months ago

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKsNew data confirm dura... Full story

Yahoo Finance • 3 months ago

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of... Full story

Yahoo Finance • 3 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story

Yahoo Finance • 3 months ago

Biggest stock movers today: UUUU, FLY, and more

[Financial chart with moving up arrow graph in stock market on blue color background] Stock futures and Treasury yields slipped early Tuesday, the last trading day of September, as investors weighed the potential impact of a looming feder... Full story

Yahoo Finance • 3 months ago

AnaptysBio splits operations into two companies

[Divorce law and inheritance separation concept. Hand separate saving money, finance, home loan, debt return with piggybank and wood house. Bank business investment. Man separate stack coin on table] M.photostock/iStock via Getty Images A... Full story

Yahoo Finance • 3 months ago

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from... Full story

Yahoo Finance • 3 months ago

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB0... Full story